Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $1,008,778.60 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Jeffrey Poulton sold 2,780 shares of the business’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $362.87, for a total transaction of $1,008,778.60. Following the completion of the sale, the executive vice president owned 57,465 shares of the company’s stock, valued at $20,852,324.55. The trade was a 4.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $359.27 on Friday. The firm has a market capitalization of $47.46 billion, a PE ratio of 1,496.96 and a beta of 0.32. The company has a current ratio of 2.54, a quick ratio of 2.49 and a debt-to-equity ratio of 4.45. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The firm’s fifty day simple moving average is $418.74 and its 200 day simple moving average is $421.35.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of hedge funds have recently modified their holdings of ALNY. Groupama Asset Managment grew its holdings in shares of Alnylam Pharmaceuticals by 160.4% in the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock worth $18,610,000 after purchasing an additional 2,483,697 shares during the last quarter. Norges Bank bought a new stake in Alnylam Pharmaceuticals during the second quarter worth about $662,837,000. Arrowstreet Capital Limited Partnership increased its holdings in shares of Alnylam Pharmaceuticals by 698.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock worth $618,158,000 after buying an additional 1,185,909 shares in the last quarter. Qube Research & Technologies Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $369,943,000. Finally, Holocene Advisors LP bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth approximately $194,616,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have commented on ALNY. Bank of America dropped their price target on Alnylam Pharmaceuticals from $530.00 to $529.00 and set a “buy” rating on the stock in a research report on Monday, January 12th. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 10th. HC Wainwright set a $570.00 target price on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, November 4th. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Thursday. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $489.00 price objective (up previously from $449.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, October 31st. Twenty-two equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $490.96.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.